EP0682027B1
(de)
*
|
1994-05-03 |
1997-10-15 |
Novartis AG |
Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
|
TW321649B
(xx)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
DK0819129T3
(da)
*
|
1995-04-03 |
2000-10-23 |
Novartis Ag |
Pyrazolderivater og fremgangsmåde til deres fremstilling
|
EP0824525B1
(en)
*
|
1995-04-27 |
2001-06-13 |
AstraZeneca AB |
Quinazoline derivatives
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
GB9508538D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
CA2224435C
(en)
*
|
1995-07-06 |
2008-08-05 |
Novartis Ag |
Pyrrolopyrimidines and processes for the preparation thereof
|
GB9624482D0
(en)
*
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
WO1997027199A1
(en)
*
|
1996-01-23 |
1997-07-31 |
Novartis Ag |
Pyrrolopyrimidines and processes for their preparation
|
HUP9901155A3
(en)
|
1996-02-13 |
2003-04-28 |
Astrazeneca Ab |
Quinazoline derivatives as vegf inhibitors
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
DE69709319T2
(de)
|
1996-03-05 |
2002-08-14 |
Astrazeneca Ab, Soedertaelje |
4-anilinochinazolin derivate
|
HU228446B1
(en)
|
1996-04-12 |
2013-03-28 |
Warner Lambert Co |
Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
WO1997049706A1
(en)
*
|
1996-06-25 |
1997-12-31 |
Novartis Ag |
SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
|
ATE384062T1
(de)
|
1996-08-23 |
2008-02-15 |
Novartis Pharma Gmbh |
Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
|
AU720135B2
(en)
|
1996-10-02 |
2000-05-25 |
Novartis Ag |
Pyrimidine derivatives and processes for the preparation thereof
|
US6225318B1
(en)
|
1996-10-17 |
2001-05-01 |
Pfizer Inc |
4-aminoquinazolone derivatives
|
JP2000505109A
(ja)
*
|
1996-11-27 |
2000-04-25 |
ファイザー・インク |
縮合二環式ピリミジン誘導体
|
CA2303280A1
(en)
*
|
1997-09-02 |
1999-03-11 |
Rajagopal Bakthavatchalam |
Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
|
JP2001522853A
(ja)
*
|
1997-11-11 |
2001-11-20 |
ファイザー・プロダクツ・インク |
抗癌剤として有用なチエノピリミジンおよびチエノピリジン誘導体
|
JPH11236333A
(ja)
*
|
1997-12-30 |
1999-08-31 |
Pfizer Prod Inc |
抗ガン剤として有用なイミダゾリン−4−オン誘導体
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
US6187777B1
(en)
*
|
1998-02-06 |
2001-02-13 |
Amgen Inc. |
Compounds and methods which modulate feeding behavior and related diseases
|
AU3053999A
(en)
|
1998-03-31 |
1999-10-25 |
Kyowa Hakko Kogyo Co. Ltd. |
Nitrogenous heterocyclic compounds
|
ATE265458T1
(de)
*
|
1998-06-19 |
2004-05-15 |
Pfizer Prod Inc |
Pyrrolo(2,3-d)pyrimidin-verbindungen
|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
WO2000023444A1
(en)
*
|
1998-10-21 |
2000-04-27 |
Abbott Laboratories |
5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
|
US6174903B1
(en)
|
1998-12-28 |
2001-01-16 |
Pfizer Inc. |
Imidazolidin-4-one derivatives useful as anticancer agents
|
UA71945C2
(en)
*
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
EP1192151B1
(en)
|
1999-07-09 |
2007-11-07 |
Glaxo Group Limited |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
OA12010A
(en)
*
|
1999-09-15 |
2006-04-19 |
Warner Lambert Co |
Pteridinones as kinase inhibitors.
|
GB9925958D0
(en)
*
|
1999-11-02 |
1999-12-29 |
Bundred Nigel J |
Therapeutic use
|
SK287401B6
(sk)
|
1999-11-05 |
2010-09-07 |
Astrazeneca Ab |
Deriváty chinazolínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
|
JP2001142235A
(ja)
|
1999-11-17 |
2001-05-25 |
Fuji Denki Gazo Device Kk |
電子写真用感光体
|
DK1235830T3
(da)
|
1999-12-10 |
2004-03-29 |
Pfizer Prod Inc |
Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer
|
JP2003535867A
(ja)
|
2000-06-06 |
2003-12-02 |
ファイザー プロダクツ インコーポレイテッド |
抗癌剤として有用なチオフェン誘導体
|
MXPA03000068A
(es)
|
2000-06-26 |
2003-09-25 |
Pfizer Prod Inc |
Compuestos de pirrolo (2,3-d)pirimidina como agentes inmunosupresores.
|
HUP0302221A3
(en)
|
2000-09-20 |
2004-01-28 |
Merck Patent Gmbh |
4-amino-quinazolines
|
PT1415987E
(pt)
|
2000-10-20 |
2007-05-31 |
Eisai R&D Man Co Ltd |
Compostos contendo aneis aromáticos azotados utilizados como agentes anti-cancerígenos.
|
DE60212487T2
(de)
|
2001-04-13 |
2006-12-21 |
Pfizer Products Inc., Groton |
Bizyklisch substituierte 4-Aminopyridopyrimidinderivate
|
US7301023B2
(en)
|
2001-05-31 |
2007-11-27 |
Pfizer Inc. |
Chiral salt resolution
|
WO2003000194A2
(en)
|
2001-06-21 |
2003-01-03 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
CZ294535B6
(cs)
*
|
2001-08-02 |
2005-01-12 |
Ústav Experimentální Botaniky Avčr |
Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
|
US7829566B2
(en)
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
DE60320933D1
(de)
*
|
2002-01-10 |
2008-06-26 |
Bayer Healthcare Ag |
Rho-kinase inhibitoren
|
MXPA04006882A
(es)
|
2002-01-17 |
2004-12-06 |
Neurogen Corp |
Analogos substituidos de quinazolin-4-ilamina como moduladores de receptores de capsaicina.
|
JP4469179B2
(ja)
|
2002-01-23 |
2010-05-26 |
バイエル ファーマセチカル コーポレーション |
Rhoキナーゼ阻害剤としてのピリミジン誘導体
|
DE60318177T2
(de)
|
2002-01-23 |
2008-10-09 |
Bayer Pharmaceuticals Corp., West Haven |
Rho-kinase inhibitoren
|
JP2003238561A
(ja)
|
2002-02-13 |
2003-08-27 |
Fuji Denki Gazo Device Kk |
キノメタン化合物
|
BR0308162A
(pt)
|
2002-03-01 |
2004-12-07 |
Pfizer |
Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
WO2004047843A1
(en)
|
2002-11-26 |
2004-06-10 |
Pfizer Products Inc. |
Method of treatment of transplant rejection
|
EP1610778A4
(en)
|
2003-01-17 |
2006-05-31 |
Threshold Pharmaceuticals Inc |
TREATMENT OF BENIGNER PROSTATE HYPERPLASIA
|
FR2851248B1
(fr)
*
|
2003-02-18 |
2005-04-08 |
Aventis Pharma Sa |
Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
|
OA13170A
(en)
|
2003-05-22 |
2006-12-13 |
Pharmacia Italia Spa |
Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
|
CA2535620A1
(en)
*
|
2003-08-15 |
2005-02-24 |
Irm Llc |
6-substituted anilino purines as rtk inhibitors
|
US7338957B2
(en)
*
|
2003-08-28 |
2008-03-04 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
ATE412655T1
(de)
|
2003-08-29 |
2008-11-15 |
Pfizer |
Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
|
US7419978B2
(en)
|
2003-10-22 |
2008-09-02 |
Bristol-Myers Squibb Company |
Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
|
EP1683785B1
(en)
|
2003-11-11 |
2013-10-16 |
Eisai R&D Management Co., Ltd. |
Urea derivative and process for producing the same
|
AP2006003619A0
(en)
|
2003-12-23 |
2006-06-30 |
Pfizer |
Novel quinoline derivatives
|
JPWO2005095419A1
(ja)
*
|
2004-04-01 |
2008-02-21 |
武田薬品工業株式会社 |
チアゾロピリミジン誘導体
|
MXPA06013805A
(es)
|
2004-05-27 |
2007-02-02 |
Pfizer Prod Inc |
Derivados de pirrolopirimidina de utilidad en el tratamiento contra el cancer.
|
WO2005118588A1
(ja)
*
|
2004-06-02 |
2005-12-15 |
Takeda Pharmaceutical Company Limited |
縮合複素環化合物
|
ZA200610669B
(en)
*
|
2004-06-02 |
2008-06-25 |
Takeda Pharmaceutical |
Fused heterocyclic compound
|
EP1797881B1
(en)
|
2004-09-17 |
2009-04-15 |
Eisai R&D Management Co., Ltd. |
Medicinal composition with improved stability and reduced gelation properties
|
CN101124228B
(zh)
*
|
2004-12-14 |
2011-06-15 |
阿斯利康(瑞典)有限公司 |
用作抗肿瘤药物的吡唑并嘧啶化合物
|
WO2006091450A1
(en)
|
2005-02-18 |
2006-08-31 |
Lexicon Genetics Incorporated |
4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
|
JP2008531542A
(ja)
*
|
2005-02-24 |
2008-08-14 |
ファイザー・プロダクツ・インク |
抗癌剤として有用な二環式複素芳香族誘導体
|
SI1899334T1
(sl)
*
|
2005-06-17 |
2009-04-30 |
Janssen Pharmaceutica Nv |
Naftiridinske spojine
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
ES2378473T3
(es)
|
2005-12-21 |
2012-04-12 |
Abbott Laboratories |
Compuestos antivirales
|
US7915411B2
(en)
|
2005-12-21 |
2011-03-29 |
Abbott Laboratories |
Anti-viral compounds
|
DE602006015861D1
(de)
|
2005-12-21 |
2010-09-09 |
Abbott Lab |
Antivirale verbindungen
|
MX2008012482A
(es)
*
|
2006-03-31 |
2008-10-10 |
Abbott Lab |
Compuestos de indazol.
|
KR20090017498A
(ko)
*
|
2006-04-04 |
2009-02-18 |
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 |
Pi3 키나제 길항물질
|
CA2652442C
(en)
|
2006-05-18 |
2014-12-09 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
EP1889847A1
(en)
*
|
2006-07-10 |
2008-02-20 |
DeveloGen Aktiengesellschaft |
Pyrrolopyrimidines for pharmaceutical compositions
|
KR101472600B1
(ko)
|
2006-08-28 |
2014-12-15 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암에 대한 항종양제
|
RU2009126576A
(ru)
|
2006-12-12 |
2011-01-20 |
Такеда Фармасьютикал Компани Лимитед (Jp) |
Конденсированное гетероциклическое соединение
|
US8236950B2
(en)
|
2006-12-20 |
2012-08-07 |
Abbott Laboratories |
Anti-viral compounds
|
CA2676796C
(en)
|
2007-01-29 |
2016-02-23 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
US8952035B2
(en)
|
2007-11-09 |
2015-02-10 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
US20090233937A1
(en)
|
2008-03-12 |
2009-09-17 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic compound
|
UA101676C2
(uk)
|
2008-07-31 |
2013-04-25 |
Дженентек, Инк. |
Піримідинові сполуки, композиції і способи застосування
|
MX2011001904A
(es)
|
2008-08-20 |
2011-03-29 |
Pfizer |
Compuestos de pirrolo[2,3-d]pirimidina.
|
TW201014860A
(en)
*
|
2008-09-08 |
2010-04-16 |
Boehringer Ingelheim Int |
New chemical compounds
|
KR101126736B1
(ko)
*
|
2008-11-27 |
2012-04-12 |
주식회사 레고켐 바이오사이언스 |
티로신 키나아제 저해 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 포함하는 약학적 조성물
|
KR102088588B1
(ko)
|
2009-01-16 |
2020-03-12 |
엑셀리시스, 인코포레이티드 |
N-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
|
DE102009005193A1
(de)
*
|
2009-01-20 |
2010-07-22 |
Merck Patent Gmbh |
Neue heterocyclische Verbindungen als MetAP-2 Inhibitoren
|
WO2010094695A1
(en)
*
|
2009-02-17 |
2010-08-26 |
Boehringer Ingelheim International Gmbh |
Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
KR101469334B1
(ko)
|
2009-11-12 |
2014-12-04 |
에프. 호프만-라 로슈 아게 |
N-9-치환된 퓨린 화합물, 조성물 및 사용 방법
|
WO2011058025A1
(en)
|
2009-11-12 |
2011-05-19 |
F. Hoffmann-La Roche Ag |
N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
|
MX2012009074A
(es)
*
|
2010-02-05 |
2012-08-23 |
Pfizer |
Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
|
BR112012032462A2
(pt)
|
2010-06-25 |
2016-11-08 |
Eisai R&D Man Co Ltd |
agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
|
SG187956A1
(en)
*
|
2010-08-27 |
2013-03-28 |
Merck Patent Gmbh |
Furopyridine derivatives
|
WO2012080990A1
(en)
|
2010-12-17 |
2012-06-21 |
Nerviano Medical Sciences S.R.L. |
Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
|
CN103998040B
(zh)
|
2011-03-04 |
2017-03-29 |
江苏康缘药业股份有限公司 |
炔基取代的喹唑啉化合物及其使用方法
|
BR112013021941B1
(pt)
|
2011-04-18 |
2022-11-16 |
Eisai R & D Management Co., Ltd |
Agente terapêutico para tumor
|
EP3444363B1
(en)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
WO2013124025A1
(en)
*
|
2012-02-21 |
2013-08-29 |
Merck Patent Gmbh |
Furopyridine derivatives
|
CN104781260A
(zh)
|
2012-09-26 |
2015-07-15 |
拜耳制药股份公司 |
用于治疗过度增殖性障碍的取代的吲唑-吡咯并嘧啶
|
CA2885783A1
(en)
|
2012-09-26 |
2014-04-03 |
Bayer Pharma Aktiengesellschaft |
Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases
|
CA2889866A1
(en)
|
2012-12-21 |
2014-06-26 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
JP2016506944A
(ja)
*
|
2013-02-01 |
2016-03-07 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
置換ピラゾロピリミジニルアミノ−インダゾール
|
WO2014145576A2
(en)
|
2013-03-15 |
2014-09-18 |
Northwestern University |
Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
|
CN105264380B
(zh)
|
2013-05-14 |
2017-09-05 |
卫材R&D管理有限公司 |
用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
|
NZ729137A
(en)
|
2014-08-04 |
2022-07-29 |
Nuevolution As |
Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
|
EP3524595B1
(en)
|
2014-08-28 |
2022-08-10 |
Eisai R&D Management Co., Ltd. |
High-purity quinoline derivative and method for manufacturing same
|
AU2016224583B2
(en)
|
2015-02-25 |
2021-06-03 |
Eisai R&D Management Co., Ltd. |
Method for suppressing bitterness of quinoline derivative
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
MX2017015896A
(es)
|
2015-06-16 |
2018-08-09 |
Eisai R&D Man Co Ltd |
Agente anticancerigeno.
|
GB201520499D0
(en)
*
|
2015-11-20 |
2016-01-06 |
Medical Res Council Technology |
Compounds
|
CN106831779B
(zh)
*
|
2015-11-28 |
2019-07-19 |
南昌弘益药业有限公司 |
一类jak激酶抑制剂的新化合物
|
WO2021124277A1
(en)
|
2019-12-20 |
2021-06-24 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
AU2021249530A1
(en)
|
2020-03-31 |
2022-12-01 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
MX2022012260A
(es)
|
2020-03-31 |
2022-11-30 |
Nuevolution As |
Compuestos activos frente a receptores nucleares.
|
KR20230170039A
(ko)
|
2021-04-13 |
2023-12-18 |
뉴베일런트, 아이엔씨. |
Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클
|